Introduction {#Sec1}
============

Morphine is a naturally occurring opioid alkaloid. It is the first choice analgesic for severe pain and can be used for preoperative sedation. Morphine can be administered via different routes intravenously (IV), intramuscularly (IM), subcutaneously (SC), orally, and rectally. There are two major formulations of oral morphine: immediate release, which has extensive inter-individual variation for bioavailability and controlled release morphine, which is less variable. Bioavailability is approximately 30--40 % \[[@CR1]\].

Dosing varies according to the age, route of administration, and is based on body weight \[[@CR2]--[@CR4]\]. Due to patients' varied response to pain, morphine dose is usually titrated according to clinical response. Paediatric dosing for drugs is sometimes determined from adult pharmacokinetic studies. However, results from adults are difficult to extrapolate to children, because the physiological makeup of the two age groups is different. Pharmacokinetic studies in children therefore help to ensure that the appropriate drug dose is administered. Doses are usually calculated from mean pharmacokinetic values. There is however often significant variability in pharmacokinetics due to factors such as age \[[@CR5]\], weight \[[@CR6]\], disease \[[@CR7]\], and ethnicity/genotype \[[@CR8]\]. Recent advances in research has resulted in the development of PK--models to ensure the appropriate individualisation of dosing in children \[[@CR9]\].

We have previously evaluated inter-individual variation in the clearance of midazolam \[[@CR10]\]. We wished to explore inter-individual variation in morphine clearance in paediatric patients and we therefore performed a systematic review of pharmacokinetic studies in paediatric patients involving morphine. The metabolite morphine-6-glucuronide (M6G) is more potent as an analgesic than morphine itself. We therefore also looked at M6G to morphine ratios.

Methods {#Sec2}
=======

A systematic literature search was performed to identify all papers describing the clearance of morphine in children. The following databases were utilised; MEDLINE (1946 to May 2013), EMBASE (1974 to May 2013), International Pharmaceutical Abstracts (1970 to April 2013), CINAHL, and Cochrane Library. The databases were searched separately and combined together to remove duplications. The search strategy included all languages and involved the keywords "morphine AND "child\*" OR "p\*ediatric\* OR "infant\*" OR "new-born\*" OR "neonate\*" OR "adolescent\*" \[[@CR11]\] AND "pharmacokinetic\*" OR "clearance" OR "half-life" OR "absorption" OR "distribution" OR "metabolism" OR "elimination" OR \*".

Inclusion criteria were original research studies assessing the pharmacokinetics of morphine in children up to the age of 18 years. We excluded the following: review articles, editorials, conference abstracts, studies in adults aged 18 years and over, and studies that involved adults and paediatric patients where the paediatric data was not presented separately. Studies in which morphine was not administered intravenously were also excluded.

Data such as, number of patients, ethnicity, dose, and clearance were extracted. The mean/median clearance, as well as both the minimum and maximum clearance values were noted. The variation ratio was calculated from the range of clearance (maximum clearance divided by the minimum clearance).The coefficient of variation (CV) was extracted from the paper if given. If individual data was presented, then the CV was calculated using the formula \[[@CR10], [@CR12]\].$$\documentclass[12pt]{minimal}
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which allows for the fact that clearance is usually log normally distributed in children. If individual data was not available, then CV was estimated by dividing the standard deviation by the mean of clearance, i.e., normal distribution assumed. The variation ratio for M6G/M was calculated by dividing the maximum M6G/M by the minimum M6G/M. Patients were divided into two groups: (1) critically ill if they were in an intensive care unit and (2) non-critically ill which included other groups. We also contacted original authors by email if their paper did not give the full range of clearance values but gave mean clearance values.

Results {#Sec3}
=======

A total of 2040 articles were identified, but only 28 articles (studies) met the inclusion criteria \[[@CR5], [@CR7], [@CR13]--[@CR38]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of the search performed

Eight studies were excluded after quality assessment (Supplementary table [3](#MOESM1){ref-type="media"}) \[[@CR19], [@CR23], [@CR29]--[@CR31], [@CR35]--[@CR37]\]. For one study, some of the data were excluded \[[@CR5]\]. A total of 20 studies were included after quality assessment.

The majority of the studies (19) used non-compartmental methods. Only one used a two-compartmental model \[[@CR34]\]. Ethnicity was not described in any study. The CV was not stated in any study. Ten studies provided individual data allowing calculation of CV \[[@CR5], [@CR7], [@CR13]--[@CR16], [@CR18], [@CR24], [@CR28], [@CR32]\]. In six studies, only the standard deviation (SD) was reported, and therefore, CV was estimated, assuming normal distribution \[[@CR17], [@CR20]--[@CR22], [@CR26], [@CR34]\]. Three studies did not report either SD or CV of morphine clearance \[[@CR25], [@CR27], [@CR33]\].

All the studies, except two, involved critically ill patients \[[@CR5], [@CR27]\]. Thirteen studies reported morphine clearance in 228 critically ill neonates (Table [1](#Tab1){ref-type="table"}) \[[@CR5], [@CR13]--[@CR18], [@CR20]--[@CR22], [@CR24]--[@CR26]\].Table 1Morphine clearance in critically ill neonatesAge groupNumber of patientsRange of weight\
(kg)Mean clearance\
(ml min^-1^ kg^-1^)SDCoefficient of variation\
(%)Range of clearance\
(ml min^-1^ kg^-1^)Variation ratio\
in clearanceCommentsStudy Preterm neonates90.9--220.4162--32Individual data availableHartley et al 1993 \[[@CR13]\]82--451.8472--63Individual data availableMikkelsen et al 1994 \[[@CR14]\]260.7--441.7382--105Individual data availableBarrett et al 1991 \[[@CR15]\]101-431.8960.5--714Individual data availableChay et al 1992 \[[@CR16]\]311^a^21500.8--68--Saarenmaa et al 2000 \[[@CR17]\]190.7--253711--1414Individual data availableBarrett et al 1996 \[[@CR18]\]112--4129753--3512--Geiduschek et al 1997 \[[@CR20]\]10^c^\
7^c^1^b^\
2^b^3\
103\
497\
42NANA--Bhat et al 1990 \[[@CR21]\]9^c^\
13^c^\
13^c^1^b^\
1^b^\
2^b^2\
3\
51\
2\
247\
66\
40NA\
NA\
NANA\
NA\
NA--Scott et al 1999 \[[@CR22]\] Term neonates60.5--462354--103Individual data availableLynn et al 1987 \[[@CR24]\]182--57NANA3--145--McRorie et al 1992 \[[@CR25]\]52--451.8552--74Individual data availableMikkelsen et al 1994 \[[@CR14]\]53--421.4740.8--45Individual data availableChay et al 1992 \[[@CR16]\]101--554871--1313Individual data availablePokela et al 1993 \[[@CR5]\]122--482242--3920--Koren et al 1985 \[[@CR26]\]33^b^161065NANA--Bhat et al 1990 \[[@CR21]\]33^b^8337NANA--Scott et al 1999 \[[@CR22]\]*NA* not available^a^Median^b^Mean^c^Two groups of preterm neonates

Details of the administration of morphine and the number of blood samples collected to calculate clearance are given in Supplementary Table [1](#MOESM1){ref-type="media"}.

Nine of the neonatal studies were in preterm neonates (*n* = 166) with CV ranging from 16 to 97 %. The CV for term neonates (*n* = 62) varied between 24 and 87 %. There was 2--14-fold inter-individual variation of clearance in preterm neonates and 3--20-fold variation in term neonates. The range in clearance is shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Mean and range of clearance for different patient age groups (for studies with individual data of CL)

There were four studies involving 53 infants (Table [2](#Tab2){ref-type="table"}) \[[@CR24], [@CR25], [@CR27], [@CR28]\].Table 2Morphine clearance in critically ill paediatric patientsAge groupNumber of patientsRange of weight\
(kg)Mean clearance\
(ml min^-1^ kg^-1^)SDCoefficient of variation\
(%)Range of clearance\
(ml min^-1^ kg^-1^)Variation ratio\
in clearanceCommentsStudyInfants102--40.7^a^NANA0.6--12--Roka et al 2008 \[[@CR27]\]53--622171344--4511Individual data availableOlkkola et al 1988 \[[@CR28]\]33--624143513--393Individual data availableLynn et al 1987 \[[@CR24]\]353--14NANANA6--295--McRorie et al 1992 \[[@CR25]\]12--11 years913--2652183926--763Individual data availableOlkkola et al 1988 \[[@CR28]\]321--4032185521--533Individual data availableNahata et al 1985 \[[@CR32]\]12--18 years350--60198749--243Individual data availableNahata et al 1985 \[[@CR32]\]1--15 years10NA34NANA19--583--Collins et al 1996 \[[@CR33]\]6--19 years18NA3614396--5910--Dampier et al 1995 \[[@CR34]\]7 months--7 years8^b^\
8^c^NA14\
235\
637\
258--22\
18--333\
2Individual data availableDagan et al 1993 \[[@CR7]\]*NA* not available^a^Median^b^Fontan repair^c^Tetralogy of Fallot (TOF)

Two of these studies involved both critically ill and non-critically ill patients (Table [3](#Tab3){ref-type="table"}).Table 3Morphine clearance in non-critically ill paediatric patientsAge groupNumber of patientsRange of weight\
(kg)Mean Clearance\
(ml min^-1^ kg^-1^)SDCoefficient of variation\
(%)Range of clearance\
(ml min^-1^ kg^-1^)Variation ratio in clearanceCommentsStudyTerm neonates103--5103.5376-163Individual data availablePokela et al 1993 \[[@CR5]\]\>28 days--23 months54--82184410-313Individual data availablePokela et al 1993 \[[@CR5]\]62--41^a^NANA0.6-12--Roka et al 2008 \[[@CR27]\]*NA* not available^a^Median

One of these studies involved both term neonates and infants with CV of 37 and 44 %, respectively \[[@CR5]\]. The other study involving infants did not report the CV. However, variation ratios in these studies were twofold and threefold \[[@CR5], [@CR27]\]. The CV of morphine clearance in critically ill infants was 35 and 134 %. The variation ratio in studies involving critically ill infants was between 2- and 11-fold.

Two studies reported clearance in 12 critically ill children \[[@CR28], [@CR32]\]. The CV in these studies was 39 and 55 %. These studies gave the full range of clearance for inter-individual children. The variation ratio of clearance was threefold for both studies. Only one study involved adolescents. The four critically ill adolescents had CV of 74 % and variation ratio of threefold \[[@CR32]\].

Three studies involved a combination of more than one age group \[[@CR7], [@CR33], [@CR34]\]. The highest CV of 39 % was in a study involving patients aged 6--19 years, whilst the lowest CV of 25 % was in patients aged 7 months--7 years. The degree of variability in clearance was between 2- and 10-fold. The coefficients of variation in different age groups are summarised in Table [4](#Tab4){ref-type="table"}.Table 4Coefficient of variation for morphine clearance in paediatricsAgeCritically ill (*n*)Non-critically ill (*n*)Preterm neonates16--97 % (166)--Term neonates24--87 % (62)37 % (10)Infants35--134 % (53)44 % (11)Children39--55 % (12)--Adolescents74 % (4)--

Three studies reported the ratio of M6G to morphine (Supplementary table [2](#MOESM1){ref-type="media"}) \[[@CR18], [@CR33], [@CR38]\]. The variation ratio in neonates ranged between 4- and 33-fold. One study in infants reported variation ratio of 12-fold.

Discussion {#Sec4}
==========

Inter-individual variation was greatest in critically ill neonates and infants. Inter-individual variation was lowest in non-critically ill patients. The variation ratio in clearance in critically ill neonates ranged from 2- to 20-fold with the coefficient of variation going up to 96 %. In infants, the variation ratio ranged from 2- to 11-fold with the coefficient of variation up to 134 %. In contrast, the variation ratio in non-critically ill patients and critically ill children and adolescents was less than fourfold (with the exception of one study in critically ill children where it was almost 10-fold).

Intravenous morphine is administered as a fixed dose bolus (50 μg/kg in neonates and 100 μg/kg in infants and children up to the age of 12 years \[[@CR4]\]. It is then given as an intravenous infusion with a fourfold variation in dosage in neonates (5--20 μg/kg/h) and lower variation in infusion rates in infants (10--30 μg/kg/h) and children (20--30 μg/kg/h). The dose is then titrated according to clinical response. Titration of dose is essential due to the large inter-individual variation in clearance. The considerable variation in M6G/M ratio especially in neonates suggests that the variation in dosage requirements in order to achieve adequate pain relief is far greater than that currently recommended.

The large inter-individual variation in critically ill neonates and infants is similar to our previous study on inter-individual variation in midazolam clearance in children. In contrast, there was, however, less inter-individual variation in critically ill children and adolescents with morphine than with midazolam. Critically ill patients tend to have impaired renal and hepatic function. Hepatic blood flow and hepatocellular function are altered, and consequently, hepatic clearance of morphine can be impaired \[[@CR39]\]. Critically ill children are also at risk of acute renal failure. Impairment of morphine clearance prolongs the drug half-life and accumulation of drugs may occur, leading to toxicity \[[@CR40]\]. Conditions such as sepsis, major surgery, and use of nephrotoxic drugs can damage the kidneys thereby altering the pharmacokinetic parameters of morphine \[[@CR41]\].

In conclusion, large inter-individual variation was seen in morphine clearance values in critically ill neonates and infants.
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